Last reviewed · How we verify
NCT05751824
Evaluating the Effect of the Automatic Surveillance System on Surveillance Rate of Colorectal Postpolypectomy Patients
NA trial testing AI based automatic surveillance (AS) system (ENDOANGEL-AS) in Artificial Intelligence in 867 participants. Not yet recruiting.
31 December 2028
Quick facts
| Lead sponsor | Renmin Hospital of Wuhan University |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | screening |
| Enrollment | 867 |
| Start date | 26 February 2023 |
| Primary completion | 31 December 2028 |
| Estimated completion | 31 December 2029 |
| Sites | 2 locations across China |
Drugs / interventions tested
- AI based automatic surveillance (AS) system (ENDOANGEL-AS)
- Manually remind the patients to review.
Conditions studied
- Artificial Intelligence — all drugs for Artificial Intelligence →
- Surveillance — all drugs for Surveillance →
Sponsor
Renmin Hospital of Wuhan University
Who can join
18 and older, any sex, with Artificial Intelligence or Surveillance. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In this study, we proposed a prospective study about the effect of the automatic surveillance system on surveillance rate of colorectal postpolypectomy patients. The enrolled patients were divided into group A with intelligent surveillance system, group B with manual reminder, and group C with natural state. The surveillance among the three groups were compared.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05751824
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of AI based automatic surveillance (AS) system (ENDOANGEL-AS)
Trials testing the same drug.
- NCT06039917 — Effect of the Automatic Surveillance System on Surveillance Rate of Patients with Gastric Premalignant Lesions · NA · recruiting
Other recruiting trials for Artificial Intelligence
Currently open trials in the same condition.
- NCT07257796 — Artificial Intelligence in Assessing Gastric Intestinal Metaplasia Via the EGGIM Score · recruiting
- NCT07308561 — The Relationship Between Quality of Life, Anxiety Levels, and Attitudes Toward Artificial Intelligence Among Women Under · recruiting
- NCT07261618 — AI-Assisted 2D Fetal Brain Ultrasound for Intracranial Anomaly Detection · active not recruiting
- NCT07098884 — Artificial Intelligence for Pathology Diagnosis and Prognosis Prediction of Lung Nodule Using Smartphone Photos · recruiting
- NCT06978348 — Research on Early Prediction Model of Ischemic Cerebrovascular Disease Based on Artificial Intelligence Technology. · recruiting
Other Renmin Hospital of Wuhan University trials
Trials by the same sponsor.
- NCT07587294 — Efficacy and Safety of Ultrasound Modulation of Stellate Ganglion for the Prevention of Ventricular Arrhythmia in Patien · NA · not yet recruiting
- NCT07269509 — Evaluation of the Efficacy and Safety of an Intensified Strategy of Intratonsillar Immunotherapy (ITIT) for Allergic Rhi · NA · not yet recruiting
- NCT07151560 — Efficacy and Safety of Two Bladder-preserving Treatment Durations With Disitamab Vedotin Plus Toripalimab Combination in · Phase 2 · not yet recruiting
- NCT07085221 — Digital Out-of-hospital Management on Clinical Outcomes in Patients With Early Cardiogenic Shock · NA · recruiting
- NCT06614985 — The Efficacy and Safety of Treatment With Telitacicept in Primary Membranous Nephropathy · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05751824 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Renmin Hospital of Wuhan University
- Last refreshed: 9 March 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05751824.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing